Shigehiro Koganemaru

机构：National Cancer Center Hospital East · ORCID：0000-0003-1323-4896

发表论文 84 篇 · 总被引 352 次 · h-index 10

代表论文

• Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer (2024 · Gastric Cancer · 被引 13)
• The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer (2024 · Cancer Research Communications · 被引 9)
• IDeate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors. (2025 · Journal of Clinical Oncology · 被引 4)
• A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers. (2025 · Journal of Clinical Oncology · 被引 4)
• Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC). (2026 · Journal of Clinical Oncology · 被引 2)
• Efficacy and Safety of Investigational Treatments in Contemporary Early-Phase Clinical Trials for Japanese Gynecologic Cancers: A Single-Institution Retrospective Analysis (2026 · JCO oncology advances.)